Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Esomeprazole strontium - Hanmi Pharmaceutical

Next Previous
Drug Profile

Esomeprazole strontium - Hanmi Pharmaceutical

Alternative Names: DR esomeprazole; Esomeprazole strontium delayed-release; Esomeprazole strontium tetrahydrate; Esomezol; HIP1601

Latest Information Update: 02 Oct 2021

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Hanmi Pharmaceutical
  • Class 2 pyridinylmethylsulfinylbenzimidazoles; Anti-inflammatories; Antibacterials; Antiulcers; Gastric antisecretories; Small molecules
  • Mechanism of Action Proton pump inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Duodenal ulcer; Gastric ulcer; Gastro-oesophageal reflux; Helicobacter infections; NSAID-induced ulcer; Zollinger-Ellison syndrome

Most Recent Events

  • 26 Nov 2020 Hanmi Pharmaceutical completes a phase III trial in Gastro-oesophageal-reflux (Combination therapy) in South Korea (NCT04080726)
  • 20 Feb 2020 Hanmi Pharmaceutical completes a phase I trial in esomeprazole strontium (In volunteers) in South Korea (PO) (NCT04204629)
  • 13 Jan 2020 Hanmi Pharmaceutical initiates a phase I trial for esomeprazole strontium (In volunteers) in South Korea (PO) (NCT04204629)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top